An interventional study of extracorporeal life support and standard ACLS in Out-of-hospital Cardiac Arrest (OHCA), sponsored by Taipei Medical University Shuang Ho Hospital. Recruiting at 2 sites in Taiwan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Taipei Medical University Shuang Ho Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Out-of-Hospital Cardiac Arrest with a site in Taiwan — 9 open to participants now, 10 under way, none of them phase 3. Out-of-Hospital Cardiac Arrest · Taiwan.
Among the 23 studies in Out-of-Hospital Cardiac Arrest with a site in Taiwan, this one is the 5th largest by planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2024, is one of 12 with no phase, and was the 16th registered.
314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.
Browse Out-of-Hospital Cardiac Arrest studies →9 of the 23 studies in Out-of-Hospital Cardiac Arrest with a site in Taiwan are open now. Recruiting first, the newest first:
Far Eastern Memorial Hospital · Sites in Taiwan
Ages 20+
Jen-Tang Sun · Sites in Taiwan
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 18–60
National Taiwan University Hospital · Sites in Taiwan
Ages 18–99 · Healthy volunteers
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 66 Out-of-Hospital Cardiac Arrest studies recruiting now, 46 (70%) set no upper age limit and 13 (20%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2024.
This study's planned enrollment of 332 is above the median of 218 across 179 interventional studies indexed under Out-of-Hospital Cardiac Arrest.
Median enrollment 132 across the 13 interventional studies, 325 across the 10 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 23 has an industry lead sponsor. The 6 most frequent:
Taipei Medical University Shuang Ho Hospital is the lead sponsor of 102 studies on the registry; 18 are open to participants now.
Taipei Medical University Shuang Ho Hospital has 1 study filed under Out-of-Hospital Cardiac Arrest — fewer than ten, so there is no comparison to draw.
2 of the studies in Out-of-Hospital Cardiac Arrest with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06856018National Taiwan University HospitalArtificial Intelligence Cerebral Gray-white Matter Ratio Module Usage in Hsinchu District Hsinchu District Using an Artificial Intelligence Cerebral Gray-white Matter Ratio Module | 2026-12-31 |
| NCT06672315Jen-Tang SunApplication of Transesophageal Echocardiography in Pre-hospital Cardiac Arrest Patients | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Out-of-Hospital Cardiac Arrest with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the clinical trial is to learn if early extracorporeal life support ( ECLS ) will save more out-of-hospital cardiac arrest ( OHCA ) patients with good neurological outcome. It will also learn if emergency ECLS is safe in the OHCA rescue. Researchers aim to investigate if emergency total ECLS is better than standard advanced cardiac life support ( ACLS ) first, followed by bailout ECMO if required, for survival with favorable neurological outcome in OHCA patients. Participants meeting criteria of OHCA with witness, bystander CPR, shockable initial rhythm with repeated defibrillation, and transport time less than 30 min will be compared between total ECLS versus standard ACLS first with bailout ECMO protocols. All participants will receive emergency interventional coronary revascularization , intensive care unit therapy , cardiac ward care and up to 180 days of clinical follow up after survival .
Out-of-hospital cardiac arrest ( OHCA ) is a highly lethal emergency, unless return of spontaneous circulation ( ROSC ) is timely achieved by efficient and effective resuscitation. Nevertheless, despite advanced cardiopulmonary resuscitation ( CPR ) with mechanical chest compression, assisted ventilation and automatic external defibrillation, the survival of OHCA patients remains below 10%. Extracorporeal membranous oxygenation ( ECMO ) facilitated life support ( ECLS ) could help hemodynamic stability and improve significantly the survival of refractory OHCA to 25-40 %. On the other hand, the precise role and timing of the ECLS during the emergency management of OHCA remains largely unestablished.
In the present study, we hypothesized that emergency total ECLS is superior to standard ACLS with ECMO bailout for survival with favorable neurological outcome in refractory out-of-hospital cardiac arrest. All OHCA patients meeting the including criteria, i.e. age 18-75 years, witnessed cardiac arrest with bystander CPR, initial shockable rhythm as ventricular fibrillation or pulseless ventricular tachycardia ( VF/pVT ), repeated defibrillation shocks and escorted transportation within 30 minutes from 119 call to arriving emergency department ( ED ) in the hospital would be recruited. Eligible patients will be consecutively randomized at ED in 1:1 ratio, stratified by hospitals, into emergency total ECLS group and standard ACLS with ECMO bailout group. Informed consent is waived in the life-threatening emergency condition. For emergency total ECLS group, OHCA patients will receive early implantation and initiation of ECMO circulation within 15 minutes after randomization or up to 45 minutes after 119 call. For standard ACLS with ECMO bailout group, OHCA patients will receive standard ACLS for at least 45 minutes after collapse or 119 call or at least 15 minutes after ED arrival before calling for bailout ECMO if required. Following return of spontaneous systemic circulation (ROSC) or depending on ECMO circulation, both groups would be transferred to brain and chest computer tomography screening, emergency coronary revascularization intervention and subsequent intensive cardiac care with targeted hypothermia management. Survivals will be treated with guideline directed medical therapy for reduced ejection fraction heart failure and/or implantable cardioverter-defibrillator implantation for prevention of recurrent VT/VF in wards. All survivals will be followed up for medical and neurological status at 30 days, 90 days and 180 days after discharge.
Primary endpoint is survival with favorable neurological outcome at 30 days. Secondary endpoints are survival to discharge with favorable neurological outcome, survival with favorable neurological outcome at 180 days, total duration of cardiopulmonary resuscitation ( CPR ), total duration of mechanical ventilation, total duration of intensive care unit stay, total duration of hospitalization. Safety endpoints will be incidence of serious adverse events related to prolonged CPR, prolonged ischemia, and ECMO systemic perfusion and coronary reperfusion.
The number of subjects to be enrolled according to the primary endpoint of 30 days survival with favorable neurological outcome. With a power of 80%, accepting the level of statistical significance at alpha= 0.05 and based on two-sided Chi-Square test, we estimated 166 participants per arm are needed. This is based on the 30% success rate and 15% success rate of 30-day survival with good neurological outcome of emergency total ECLS intervention and standard ACLS with bailout ECMO (if required) intervention, according to previous trials, plus a 10% drop out rate. Based on two-tailed test, p less than 0.05 is considered statistical significance. If interim analysis is deemed necessary, the significance level will be adjusted accordingly using Bonferroni method. Because of no interim analysis and no stopping point in ITT protocol, there is no criteria for premature termination of the trial. The missing data of the primary and secondary efficacy outcomes will be considered as failure for ITT analysis. Last observations carry forward method will be adapted for the missing data of repeated measurements. The data record will be monitored and audited by the Institutional Review Board of the TMU Shuangho hospital as well as the Data and Safety Monitoring Plan committee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Emergency total extracorporeal life support ( ECLS ) in cardiopulmonary resuscitation of OHCA patients with refractory ventricular fibrillation or pulseless ventricular tachycardia
Procedure: extracorporeal life support
Emergency standard advanced cardiac life support ( ACLS ) in cardiopulmonary resuscitation of OHCA patients with refractory ventricular fibrillation or pulseless ventricular tachycardia. Bailout ECMO allowed after at least 45 minutes of CPR since collapse and 119 call or at least 15 minutes since arrival at emergency department
Procedure: standard ACLS
ECMO supported life support for cardiopulmonary resuscitation in refractory OHCA
Standard ACLS in cardioplumonary resuscitation of refractory OHCA
The rate of survival with favorable neurological outcome ( modified Rankin score less than 3 or cerebral performance category scale 1 or 2 ) at 30 days after discharge from hospital, in percentage
After survival discharge from hospital, clinical followup at out-patient clinic or by visual phone interview is conducted to assess medical health status as well as neurological status of the patients at 30 days after discharge from hospital. Survival with favorable neurological outcome ( i.e. modified Rankin score less than 3 or cerebral performance category scale 1 or 2 ) is to be measured as percentage of all randomized patients fulfilling inclusion criteria and without any exclusion criteria.
Time frame: From randomization to 30 days after survival discharge from hospital
Total duration of cardioplumonary resuscitation from on-site CPR by EMS till the stable ROSC or initiation of ECMO life support or the decease of the subject at emergency department up to 30 days after randomization, in minutes
total duration of standard cardiopulmonary resuscitation ( CPR ) is counted from the start of on-site CPR by emergency medical service ( EMS ) till the stable return of spontaneous circulation ( ROSC ) or initiation of ECMO life support or the decease of the subject at emergency department ( ED ) up to 30 days after randomization. The measure is in minutes.
Time frame: From the start of on-site CPR by EMS till the return of stable ROSC or the initiation of ECMO life support or the decease of the subject at the emergency department up to 30 days after randomization, in minutes
The rate of survival with favorable neurological outcome ( modified Rankin score less than 3 or CPC scale 1 or 2 ) from the date of randomization to the date of discharge from hospital up to 180 days after randomization, in percentage
At discharge from hospital, patient status is assessed as survival or mortality. The rate of survival with favorable neurological outcome ( modified Rankin score \<3 or CPC scale 1 or 2 ) is counted from the date of randomization to the date of discharge from hospital up to 180 days after randomization. The rate of survival is measured as percentage of total randomization number.
Time frame: From the date of randomization to the date of discharge from hospital up to 180 days after randomization, in percentage.
The rate of survival with favorable outcomes ( modified Rankin score less than 3 or cerebral performance category scale 1 or 2 ) at 90 days after discharge from hospital, in percentage
After patients survived and discharged from hospital, clinical followup at out-patient clinic or by visual phone interview is conducted to assess medical health as well as neurological status at 90 days after discharge. The rate of survival with favorable neurological outcome ( i.e. modified Rankin score less than 3 or cerebral performance category scale 1 or 2 ) is measured as percentage of all randomized patients fulfilling inclusion criteria and without any exclusion criteria.
Time frame: From the date of randomization to 90 days after survival discharge from hospital
The rate of survival with favorable outcomes ( modified Rankin score less than 3 or cerebral performance category scale 1 or 2 ) at 180 days, in percentage
After patients discharged from hospital, clinical followup at out-patient clinic or by visual phone interview is conducted to assess medical health as well as neurological status at 180 days after discharge. The rate of survival with favorable neurological outcome ( i.e. modified Rankin score less than 3 or cerebral performance category scale 1 or 2 ) is measured as percentage of all enrolled patients fulfilling inclusion criteria and without any exclusion criteria.
Time frame: From enrollment to the end of treatment at 180 days
total duration of mechanical ventilation from randomization to discharge from hospital or up to 180 days after randomization , in days
The total duration of assisted mechanical ventilation by volume cycle or pressure cycled artificial ventilators from randomization at the emergency department to discharge from hospital or up to 180 days after randomization, measured in days.
Time frame: From randomization at the emergency department to discharge from hospital or up to 180 days after randomization
total duration of stay in intensive care ward from randomization to discharge from hospital or up to 180 days after randomization , in days
The total duration of stay in intensive care ward from randomization to discharge from hospital or up to 180 days after randomization. The intensive care ward is to provide cardiovascular hemodynamic support, assisted mechanical ventilation, targeted temperature therapy ( if needed ) and infection control, whenever needed. The measure is in days.
Time frame: From the date of randomization to the date of discharge from hospital or up to 180 days after randomization
total duration of hospitalization from the date of randomization to the date of discharge or up to 180 days after randomization , in days
total duration of stay in the hospital from the date randomization at emergency department to the date discharge from hospital or up to 180 days after randomization, survived or deceased. The measure in in days.
Time frame: From the date of randomization to the date of discharge from hospital or up to 180 days after randomization, survived or deceased.
Started Nov 2024 (actual). Primary completion is estimated for Nov 2028, 48 months after the start.
Of 93 non-industry interventional studies with no phase under Out-of-Hospital Cardiac Arrest, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 48 months is above that.
Counting every sponsor, half of 95 studies reached it within 34 months; a quarter within 19 and three quarters within 57.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Nov 2027 → Nov 2028 and completion Nov 2027 → Jul 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Out-of-Hospital Cardiac Arrest →
Taipei Medical University Shuang Ho Hospital →